JP2009537606A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537606A5
JP2009537606A5 JP2009511518A JP2009511518A JP2009537606A5 JP 2009537606 A5 JP2009537606 A5 JP 2009537606A5 JP 2009511518 A JP2009511518 A JP 2009511518A JP 2009511518 A JP2009511518 A JP 2009511518A JP 2009537606 A5 JP2009537606 A5 JP 2009537606A5
Authority
JP
Japan
Prior art keywords
lower alkyl
mono
phenyl
amino
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537606A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/055016 external-priority patent/WO2007137981A1/en
Publication of JP2009537606A publication Critical patent/JP2009537606A/ja
Publication of JP2009537606A5 publication Critical patent/JP2009537606A5/ja
Pending legal-status Critical Current

Links

JP2009511518A 2006-05-25 2007-05-23 チロシンキナーゼ阻害剤 Pending JP2009537606A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80318206P 2006-05-25 2006-05-25
PCT/EP2007/055016 WO2007137981A1 (en) 2006-05-25 2007-05-23 Inhibitors of tyrosine kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013096740A Division JP2013189443A (ja) 2006-05-25 2013-05-02 チロシンキナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2009537606A JP2009537606A (ja) 2009-10-29
JP2009537606A5 true JP2009537606A5 (enExample) 2013-01-10

Family

ID=38255250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009511518A Pending JP2009537606A (ja) 2006-05-25 2007-05-23 チロシンキナーゼ阻害剤
JP2013096740A Pending JP2013189443A (ja) 2006-05-25 2013-05-02 チロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013096740A Pending JP2013189443A (ja) 2006-05-25 2013-05-02 チロシンキナーゼ阻害剤

Country Status (3)

Country Link
US (1) US8093259B2 (enExample)
JP (2) JP2009537606A (enExample)
WO (1) WO2007137981A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200840581A (en) * 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
TW201006823A (en) * 2008-07-14 2010-02-16 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
US20140080772A1 (en) * 2012-09-06 2014-03-20 The Board Of Regents Of The University Of Texas System Treatments for melanoma
JP7057975B2 (ja) * 2016-12-14 2022-04-21 国立大学法人信州大学 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
JP6944801B2 (ja) * 2017-03-29 2021-10-06 株式会社Ｓｃｒｅｅｎホールディングス ヒートローラおよびそれを備えた印刷装置
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CA2448320A1 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
JPWO2005063709A1 (ja) 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
CA2567686A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase

Similar Documents

Publication Publication Date Title
US20230116233A1 (en) Compounds And Compositions As Protein Kinase Inhibitors
JP2011530607A5 (enExample)
RU2315043C2 (ru) Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
RU2012124811A (ru) СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R
JP2020503299A5 (enExample)
JP2016514718A5 (enExample)
JP2008528467A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
RU2012120901A (ru) Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
WO2012000304A1 (zh) 杂环炔苯类化合物及其药用组合物和应用
JP2017535589A (ja) ２−アミノピリミジン系化合物およびその薬物組成物と使用
US20130096149A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
JP2019505595A5 (enExample)
JP2019505594A5 (enExample)
JP2016514717A5 (enExample)
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119
JP2017536342A5 (enExample)
CA2617991A1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
US20250188075A1 (en) Substituted heterocyclic csnk1 inhibitors
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
JP2020531485A5 (enExample)
RU2007144530A (ru) Применение производных пиримидиламинобензамида для лечения системного мастоцитоза